ALKS - Alkermes plc
| Previous Close | 21.43 |
| Open | 21.36 |
| Bid | 21.25 x 900 |
| Ask | 21.28 x 800 |
| Day's Range | 21.03 - 21.74 |
| 52 Week Range | 19.36 - 45.16 |
| Volume | 259,152 |
| Avg. Volume | 1,349,673 |
| Market Cap | 3.356B |
| Beta (3Y Monthly) | 1.41 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.17 |
| Earnings Date | Oct 21, 2019 - Oct 25, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 27.83 |
- Simply Wall St.
Alkermes (NASDAQ:ALKS) Has Debt But No Earnings; Should You Worry?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
- GuruFocus.com
Alkermes Plc (ALKS) Director and CEO, Alkermes plc Richard F Pops Sold $2.3 million of Shares
Director and CEO, Alkermes plc of Alkermes Plc (30-Year Financial, Insider Trades) Richard F Pops (insider trades) sold 100,000 shares of ALKS on 09/12/2019 at an average price of $22.68 a share. Continue reading...
- PR Newswire
Alkermes Announces the Appointment of Richard Gaynor, M.D. and Andy Wilson to its Board of Directors and the Retirement of Director Floyd Bloom, M.D.
DUBLIN, Sept. 13, 2019 /PRNewswire/ -- Alkermes plc (ALKS) today announced the appointment of two new independent directors, Richard Gaynor, M.D. and Frank Anders (Andy) Wilson, to the company's Board of Directors. The company also announced the retirement of Floyd Bloom, M.D., a pioneer in the field of neuroscience who contributed immensely to the legacy of innovation and scientific excellence that remains core to Alkermes' mission today. Dr. Gaynor, who currently serves as the President of Research & Development at Neon Therapeutics, brings 18 years of experience in oncology-focused industrial drug development in addition to a distinguished career in academic medicine.
- Zacks
Why Is Alkermes (ALKS) Down 3.9% Since Last Earnings Report?
Alkermes (ALKS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- Simply Wall St.
An Intrinsic Calculation For Alkermes plc (NASDAQ:ALKS) Suggests It's 49% Undervalued
In this article we are going to estimate the intrinsic value of Alkermes plc (NASDAQ:ALKS) by taking the foreast...
- Zacks
Clovis (CLVS) Q2 Earnings & Sales Lag Estimates, Shares Down
Clovis (CLVS) reports dismal second-quarter 2019 results. The company provides lower-than-expected guidance for product sales in 2019.
- Zacks
Biotech Stock Roundup: Celgene, Amgen, Gilead Impress in Q2, Other Pipeline Updates
Impressive second-quarter results by most biotech bigwigs are the key highlights of the week. Most companies also increase their annual guidance.
- PR Newswire
Diroximel Fumarate Demonstrated Significantly Improved Gastrointestinal Tolerability Profile Compared to Dimethyl Fumarate in Patients with Multiple Sclerosis
DUBLIN and CAMBRIDGE, Mass., July 30, 2019 /PRNewswire/ -- Alkermes plc (ALKS) and Biogen Inc. (BIIB) today announced positive topline results from EVOLVE-MS-2, a large, randomized, double-blind, five-week, Phase 3 study of diroximel fumarate, an investigational, novel oral fumarate with a distinct chemical structure, for relapsing-remitting multiple sclerosis (RRMS), compared to TECFIDERA® (dimethyl fumarate). Diroximel fumarate was statistically superior to dimethyl fumarate on the study's pre-specified primary endpoint, with patients treated with diroximel fumarate self-reporting significantly fewer days of key gastrointestinal (GI) symptoms with intensity scores ≥2 on the Individual Gastrointestinal Symptom and Impact Scale (IGISIS), as compared to dimethyl fumarate (p = 0.0003).
- PR Newswire
Alkermes Announces Settlement With Amneal Over VIVITROL® Patent Dispute
Under the agreement, the parties agreed to request termination of the IPR and Alkermes granted Amneal the non-exclusive right to market a generic formulation of VIVITROL in the U.S. beginning sometime in 2028 or earlier under certain circumstances. Additional terms of the agreement are confidential.
- Thomson Reuters StreetEvents
Edited Transcript of ALKS earnings conference call or presentation 25-Jul-19 12:00pm GMT
Q2 2019 Alkermes Plc Earnings Call
- Zacks
Alkermes (ALKS) Earnings and Sales Beat Estimates in Q2
Alkermes (ALKS) surpasses earnings and sales estimates in the second quarter of 2019.
- Benzinga
The Daily Biotech Pulse: Obseva Gets The Greenlight, Verastem Climbs On Licensing Deal, Merit Medical Earnings Disappoint
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on July 25) Akero Therapeutics Inc (NASDAQ: AKRO ) Anika Therapeutics ...
Motley FoolAlkermes PLC (ALKS) Q2 2019 Earnings Call Transcript
ALKS earnings call for the period ending June 30, 2019.
- Zacks
Alkermes (ALKS) Beats Q2 Earnings and Revenue Estimates
Alkermes (ALKS) delivered earnings and revenue surprises of 190.00% and 10.13%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
- Benzinga
The Daily Biotech Pulse: Setback For Bristol-Myers Squibb, Gemphire Explodes, Lilly's Nasal Low Blood Sugar Drug
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on July 24) Acasti Pharma Inc (NASDAQ: ACST ) Cardiovascular Systems ...
- PR Newswire
Alkermes Plc Reports Second Quarter 2019 Financial Results
-- Second Quarter Revenues of $279.9 Million , Primarily Driven by Approximately 24% Year-Over-Year Growth of Proprietary Product Net Sales -- -- Company Reports GAAP Net Loss per Share of $0.27 and Non-GAAP ...
- PR Newswire
Alkermes to Host Conference Call to Discuss Second Quarter 2019 Financial Results
DUBLIN , July 18, 2019 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET ( 1:00 p.m. BST ) on Thursday, July 25, 2019 , to discuss the company's ...
- Simply Wall St.
Does Alkermes plc (NASDAQ:ALKS) Have A Particularly Volatile Share Price?
If you own shares in Alkermes plc (NASDAQ:ALKS) then it's worth thinking about how it contributes to the volatility of...
- Zacks
Earnings Preview: Alkermes (ALKS) Q2 Earnings Expected to Decline
Alkermes (ALKS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Zacks
Biotech Stock Roundup: Galapagos & Hookipa Surge, AMGN Shelves Alzheimer's Study
Key highlights of the past week include collaborations and other pipeline updates.
- Zacks
ALXN or ALKS: Which Is the Better Value Stock Right Now?
ALXN vs. ALKS: Which Stock Is the Better Value Option?
- Zacks
Alkermes to Include Bipolar I Disorder in ALKS 3831 NDA
Alkermes (ALKS) plans to expand the NDA for ALKS 3831 to include the treatment of bipolar I disorder in addition to the treatment for schizophrenia.
